Cargando…

Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma

SIMPLE SUMMARY: Immune checkpoint inhibitors, which stimulate the patient’s own T-cells to attack tumor cells, have revolutionized the treatment of metastatic melanoma. However, not all melanoma patients respond to therapy possibly due to a lack of T-cells present in or entering tumor tissue. It is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ammann, Nadine L., Schwietzer, Yasmin F., Mess, Christian, Stadler, Julia-Christina, Geidel, Glenn, Kött, Julian, Pantel, Klaus, Schneider, Stefan W., Utikal, Jochen, Bauer, Alexander T., Gebhardt, Christoffer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688620/ https://www.ncbi.nlm.nih.gov/pubmed/36428768 http://dx.doi.org/10.3390/cancers14225676

Ejemplares similares

Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma
por: Geidel, Glenn, et al.
Publicado: (2022)

Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors
por: Stadler, Julia-Christina, et al.
Publicado: (2023)

Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
por: Simon, Sonja C. S., et al.
Publicado: (2020)

Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
por: Blomen, Chiara L., et al.
Publicado: (2021)

Leukocyte Count Restoration Under Dabrafenib Treatment in a Melanoma Patient With Vemurafenib-Induced Leukopenia: Case Report
por: Orouji, Elias, et al.
Publicado: (2014)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Expression of Neural Crest Markers GLDC and ERRFI1 is Correlated with Melanoma Prognosis
por: Jäger, Katharina, et al.
Publicado: (2019)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
por: Umansky, Viktor, et al.
Publicado: (2016)

Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response
por: Bernhardt, Mathias, et al.
Publicado: (2017)

Current and Future Clinical Applications of ctDNA in Immuno-Oncology
por: Stadler, Julia-Christina, et al.
Publicado: (2022)

The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation
por: Dollt, Claudia, et al.
Publicado: (2017)

Melanoma Cellular Plasticity
por: Novak, Daniel, et al.
Publicado: (2022)

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients
por: Petrova, Vera, et al.
Publicado: (2023)

Tackling malignant melanoma epigenetically: histone lysine methylation
por: Orouji, Elias, et al.
Publicado: (2018)

Update on GNA Alterations in Cancer: Implications for Uveal Melanoma Treatment
por: Larribère, Lionel, et al.
Publicado: (2020)

NF1-Dependent Transcriptome Regulation in the Melanocyte Lineage and in Melanoma
por: Larribère, Lionel, et al.
Publicado: (2021)

Involvement of platelet-derived VWF in metastatic growth of melanoma in the brain
por: Robador, Jose R, et al.
Publicado: (2021)

Systemic Therapy of Non-Resectable Metastatic Melanoma
por: Orouji, Azadeh, et al.
Publicado: (2010)

Desmoglein 2 Depletion Leads to Increased Migration and Upregulation of the Chemoattractant Secretoneurin in Melanoma Cells
por: Peitsch, Wiebke K., et al.
Publicado: (2014)

Stem Cell-Derived Models of Neural Crest Are Essential to Understand Melanoma Progression and Therapy Resistance
por: Larribère, Lionel, et al.
Publicado: (2019)

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs
por: Lepper, Alisa, et al.
Publicado: (2023)

Pre‐analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients
por: Schneegans, Svenja, et al.
Publicado: (2020)

Clonality of CD4(+) Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma
por: Arakawa, Akiko, et al.
Publicado: (2019)

Cellular Reprogramming—A Model for Melanoma Cellular Plasticity
por: Granados, Karol, et al.
Publicado: (2020)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Eosinophilic Asthma Secondary to Adjuvant Anti-PD-1 Immune Checkpoint Inhibitor Treatment in a Melanoma Patient
por: Kissoonsingh, P., et al.
Publicado: (2022)

Dual checkpoint inhibitor-associated eosinophilic enteritis
por: Yang, J., et al.
Publicado: (2019)

Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation
por: Simon, Sonja C. S., et al.
Publicado: (2023)

Neutrophils activated by membrane attack complexes increase the permeability of melanoma blood vessels
por: Liu, Xiaobo, et al.
Publicado: (2022)

Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies
por: Hüser, Laura, et al.
Publicado: (2019)

Eosinophilic Fasciitis following Checkpoint Inhibitor Therapy with Pembrolizumab
por: Zampeli, Evangelia, et al.
Publicado: (2021)

STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations
por: Kim, James, et al.
Publicado: (2020)

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
por: Wagner, Nikolaus B., et al.
Publicado: (2019)

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
por: Heppt, Markus V., et al.
Publicado: (2019)

Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI
por: Gupta, Shruti, et al.
Publicado: (2022)

Eosinophilic fasciitis as a paraneoplastic syndrome in melanoma
por: Rea, Andrea, et al.
Publicado: (2021)

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
por: Weber, Rebekka, et al.
Publicado: (2018)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
por: Koch, Elias A. T., et al.
Publicado: (2022)

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
por: Ozbay Kurt, Feyza Gul, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_usn0ljsf2qur82noaqle6nedjd